--- title: "Aterian | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 18 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286617462.md" datetime: "2026-05-15T21:16:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286617462.md) - [en](https://longbridge.com/en/news/286617462.md) - [zh-HK](https://longbridge.com/zh-HK/news/286617462.md) --- # Aterian | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 18 K Revenue: As of FY2026 Q1, the actual value is USD 18 K, missing the estimate of USD 15.82 M. EPS: As of FY2026 Q1, the actual value is USD -0.69. EBIT: As of FY2026 Q1, the actual value is USD -2.983 M. #### Consolidated Financial Performance (Three Months Ended March 31, 2026 vs. 2025) - **Net Loss**: Aterian, Inc. reported a consolidated net loss of - $6.132 million for the three months ended March 31, 2026, compared to - $3.896 million for the same period in 2025. - **Comprehensive Loss**: The comprehensive loss was - $6.201 million for the three months ended March 31, 2026, compared to - $3.761 million for the three months ended March 31, 2025. #### Continuing Operations (Three Months Ended March 31, 2026 vs. 2025) - **Net Revenue**: Decreased by $45 thousand, or 72%, to $18 thousand in 2026 from $63 thousand in 2025. - **Cost of Goods Sold**: Decreased by $5 thousand, or 40.2%, to $8 thousand in 2026 from $13 thousand in 2025. - **Gross Profit**: Decreased to 56.7% in 2026 from 79.9% in 2025. - **Sales and Distribution Expenses**: Increased to $0.3 million in 2026 from $37 thousand in 2025. - **General and Administrative Expenses**: Decreased by $435 thousand, or 13.0%, to $2.919 million in 2026 from $3.354 million in 2025. - **Operating Loss**: Was - $3.209 million in 2026, an improvement from - $3.341 million in 2025. - **Interest Expense, Net**: Increased by $0.1 million, or 29.1%, to $226 thousand in 2026 from $175 thousand in 2025. - **Change in Fair Value of Warrant Liabilities**: Was $0 in 2026, compared to - $55 thousand in 2025. - **Loss from Continuing Operations**: Was - $3.435 million in 2026, compared to - $3.419 million in 2025. #### Discontinued Operations (Three Months Ended March 31, 2026 vs. 2025) - **Net Revenue**: Decreased by $2.9 million, or 18.8%, to $12.4 million in 2026 from $15.3 million in 2025. - **Cost of Goods Sold**: Decreased by $1.5 million, or 25.1%, to $4.4 million in 2026 from $5.9 million in 2025. - **Gross Profit**: Increased to 64.3% in 2026 from 60.9% in 2025. - **Sales and Distribution Expenses**: Decreased by $2.4 million, or 25.3%, to $7.2 million in 2026 from $9.7 million in 2025. - **General and Administrative Expenses**: Decreased by $40 thousand, or 37.9%, to $65 thousand in 2026 from $105 thousand in 2025. - **Impairment Loss on Intangibles**: A non-cash impairment charge of - $3.4 million was recorded in the first quarter of 2026. - **Operating Loss**: Was - $2.699 million in 2026, a significant increase from - $355 thousand in 2025. - **Loss from Discontinued Operations, Net of Income Taxes**: Was - $2.698 million in 2026, compared to - $477 thousand in 2025. #### Cash Flow (Three Months Ended March 31, 2026 vs. 2025) - **Cash Used in Operating Activities**: Was - $0.4 million in 2026, primarily due to net cash losses from operations of - $2.0 million, partially offset by a $1.6 million inflow from changes in working capital. This compares to - $3.9 million in 2025. - **Cash Used in Investing Activities**: Was - $4 thousand in 2026, related to fixed asset purchases, compared to $0 in 2025. - **Cash Used in Financing Activities**: Was - $2.1 million in 2026, primarily from net repayments for the MidCap credit facility of - $1.8 million and insurance obligation payments of - $0.3 million. This contrasts with $0.4 million provided by financing activities in 2025. - **Total Cash and Restricted Cash**: Decreased by - $2.539 million in 2026, ending the period at $3.463 million, compared to a decrease of - $3.305 million in 2025, ending at $15.838 million. #### Strategic Outlook and Guidance Aterian, Inc. is undergoing a fundamental restructuring, including the sale of its marquee brands for $18 million in cash and a $7.0 million capital infusion, with proceeds intended to satisfy existing debt and provide working capital for remaining core businesses. Management plans a streamlined growth strategy post-change in control, focusing on the Vremi and Xtava brands. The company acknowledges substantial doubt about its ability to continue as a going concern, dependent on the successful closing of these transactions and stockholder approval. ### Related Stocks - [ATER.US](https://longbridge.com/en/quote/ATER.US.md) ## Related News & Research - [Electro-Sensors GAAP EPS of -$0.03, revenue of $2.6M](https://longbridge.com/en/news/286518577.md) - [Boston Scientific announces strategic investment in MiRus LLC | BSX Stock News](https://longbridge.com/en/news/286755970.md) - [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md) - [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md) - [Donaldson Company dividend preview: 30-year growth streak set to continue](https://longbridge.com/en/news/286805354.md)